Article
Quizartinib: a new hope in acute myeloid leukemia, an applied comprehensive review.
Future oncology (London, England) - 1 Jan 2024
Moallem Fatemeh Esmaeilpour, Gholami Chahkand Mohammad Sadra, Dadkhah Parisa Alsadat, Azarm Eftekhar, Shahrokhi Mehregan, Deyhimi Mitra Sadat, Karimi Mohammad Amin
Abstract excerpt
Acute myeloid leukemia (AML) is caused by a defective precursor leading to malignant clonal expansion, often with FMS-like tyrosine kinase-3 receptor (FLT3) mutations, particularly internal tandem duplication (ITD), which has a poor prognosis. Quizartinib, a second-generation FLT3 inhibitor, has FDA approval for relapsed/refractory AML with FLT3/ITD mutation. It has shown promise in clinical studies since 2013...
Topics
- Humans
- Leukemia, Myeloid, Acute
- fms-Like Tyrosine Kinase 3
- Phenylurea Compounds
- Protein Kinase Inhibitors
- Benzothiazoles
- Drug Resistance, Neoplasm
- Mutation
- Antineoplastic Agents
- Treatment Outcome